Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis.

Chai LY, Kullberg BJ, Earnest A, Johnson EM, Teerenstra S, Vonk AG, Schlamm HT, Herbrecht R, Netea MG, Troke PF.

PLoS One. 2014 Feb 28;9(2):e90176. doi: 10.1371/journal.pone.0090176. eCollection 2014.

2.

Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.

Wingard JR, Herbrecht R, Mauskopf J, Schlamm HT, Marciniak A, Roberts CS.

Transpl Infect Dis. 2007 Sep;9(3):182-8. Epub 2007 Jul 1.

PMID:
17605747
3.

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group..

N Engl J Med. 2002 Aug 8;347(6):408-15.

4.

Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.

Jansen JP, Kern WV, Cornely OA, Karthaus M, Ruhnke M, Ullmann AJ, Resch A.

Value Health. 2006 Jan-Feb;9(1):12-23. Erratum in: Value Health. 2006 Sep-Oct;9(5):359.

5.

Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.

Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE; European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG).; Pfizer Global Aspergillus Study Group..

Clin Infect Dis. 2005 Nov 15;41(10):1448-52. Epub 2005 Oct 13.

PMID:
16231256
6.

Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.

Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK.

Cochrane Database Syst Rev. 2014 Feb 24;(2):CD004707. doi: 10.1002/14651858.CD004707.pub3. Review.

PMID:
24563222
7.

Combination antifungal therapy for invasive aspergillosis: a randomized trial.

Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, Heinz WJ, Jagannatha S, Koh LP, Kontoyiannis DP, Lee DG, Nucci M, Pappas PG, Slavin MA, Queiroz-Telles F, Selleslag D, Walsh TJ, Wingard JR, Maertens JA.

Ann Intern Med. 2015 Jan 20;162(2):81-9. doi: 10.7326/M13-2508. Erratum in: Ann Intern Med. 2015 Mar 17;162(6):463.

PMID:
25599346
8.

Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis.

Chai LY, Kullberg BJ, Johnson EM, Teerenstra S, Khin LW, Vonk AG, Maertens J, Lortholary O, Donnelly PJ, Schlamm HT, Troke PF, Netea MG, Herbrecht R.

J Clin Microbiol. 2012 Jul;50(7):2330-6. doi: 10.1128/JCM.06513-11. Epub 2012 May 2.

9.

Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.

Sambatakou H, Dupont B, Lode H, Denning DW.

Am J Med. 2006 Jun;119(6):527.e17-24.

PMID:
16750972
10.

Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.

Wenzel R, Del Favero A, Kibbler C, Rogers T, Rotstein C, Mauskopf J, Morris S, Schlamm H, Troke P, Marciniak A.

J Antimicrob Chemother. 2005 Mar;55(3):352-61. Epub 2005 Feb 22.

PMID:
15728146
11.

Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?

Pagano L, Valentini CG, Fianchi L, Caira M.

J Chemother. 2011 Feb;23(1):5-8. Review.

PMID:
21482486
12.

Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands.

Jansen JP, Meis JF, Blijlevens NM, van't Wout JW.

Curr Med Res Opin. 2005 Oct;21(10):1535-46.

PMID:
16238893
13.

Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.

Chandrasekar PH, Cutright J, Manavathu E.

J Antimicrob Chemother. 2000 May;45(5):673-6.

PMID:
10797091
14.
15.

Voriconazole versus amphotericin B in cancer patients with neutropenia.

Jørgensen KJ, Gøtzsche PC, Johansen HK.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004707. Review. Update in: Cochrane Database Syst Rev. 2014;2:CD004707.

PMID:
16437492
16.

Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis.

Neofytos D, Railkar R, Mullane KM, Fredricks DN, Granwehr B, Marr KA, Almyroudis NG, Kontoyiannis DP, Maertens J, Fox R, Douglas C, Iannone R, Kauh E, Shire N.

PLoS One. 2015 Jun 24;10(6):e0129022. doi: 10.1371/journal.pone.0129022. eCollection 2015.

17.

Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation.

Wieland T, Liebold A, Jagiello M, Retzl G, Birnbaum DE.

J Heart Lung Transplant. 2005 Jan;24(1):102-4.

PMID:
15653389
18.

Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.

Ament AJ, Hübben MW, Verweij PE, de Groot R, Warris A, Donnelly JP, van 't Wout J, Severens JL.

J Antimicrob Chemother. 2007 Aug;60(2):385-93. Epub 2007 Jun 7.

PMID:
17561501
19.
20.

Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.

[No authors listed]

Prescrire Int. 2004 Feb;13(69):13-6.

PMID:
15055210

Supplemental Content

Support Center